RNS Number : 5353C Oncimmune Holdings PLC 22 January 2018
22 January 2018
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Result of General Meeting
No ngham, UK - 22 January 2018:Oncimmune Holdings plc (AIM: ONC.L)O, ncimmune Holdings plc (AIM: ONC.L), a leading early cancer detec!on company developing and commercialising its proprietaryEarlyCDT®liquid biopsy pla%orm technology, announces that at the Company's General Mee!ng held earlier today, all resolutions were duly passed.
The General Mee!ng was called to consider resolu!ons to grant authori!es from shareholders to allot the ordinary shares pursuant to the subscrip!on for new ordinary shares by Genos!cs Company Limited as announced by the Company on 2 January 2018.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officercontact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Giles Balleny, Hugh Kingsmill Moore +44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson +44 (0)20 7332 2500
Berenberg (Joint Broker)
Toby Flaux, Charlotte Sutcliffe +44 (0)20 3207 7800
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey NevilleOncimmune@consilium-comms.com+44 (0)20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detec!on company developing and commercialising its proprietary EarlyCDT® pla%orm technology. Oncimmune has pioneered the development of autoan!body tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product,EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold.EarlyCDT®-Lungis available through physicians in the US and also privately in the UK and other regions.EarlyCDT®-Lungis being used in the largest ever randomised trial for the early detec!on of lung cancer using biomarkers, the Na!onal Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokersE.arlyCDT®tests for liver and ovarian cancer are in development.
Oncimmune, headquartered in NoDngham, United Kingdom with tes!ng facili!es in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visitwww.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMFLLFLVFFLBBB
Oncimmune Holdings plc published this content on 22 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 January 2018 11:34:05 UTC.
Original documenthttp://ir1.euroinvestor.com/IR/Files/RNSNews/30896564/OncimmuneHoldingsPlc_13787636.pdf
Public permalinkhttp://www.publicnow.com/view/B560934AF7689509BD68FA4788DDF874BF8F0DF7